Evidence map›Paper›PMID 42117531›Full record

ArticleACS applied materials & interfaces2026

Lipid Nanoparticle Surface Engineering with Heparosan Polysaccharides for Safe and Effective mRNA Delivery

Yuxin He, Lin Wang, Rameswari Velayutham, Trisha I Valerio, Samantha D Ricketts, Yuanhong Sun, Anand C Annan, James Bowman, Thao Tran, Mobina Mohammadnejad and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuxin HeStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Lin WangStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.ORCID 0000-0003-4636-8225
Rameswari VelayuthamDepartment of Pathology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
Trisha I ValerioStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Samantha D RickettsDepartment of Pathology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
Yuanhong SunStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Anand C AnnanDepartment of Pathology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
James BowmanStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Thao TranStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Mobina MohammadnejadStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Kaili LiuStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Wei R ChenStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Dixy E GreenDepartment of Biochemistry and Physiology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
Kar-Ming FungDepartment of Pathology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
Paul L DeAngelisDepartment of Biochemistry and Physiology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma 73104, United States.
Stefan WilhelmStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.ORCID 0000-0003-2167-6221

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Use of 3D Quantitative Optical Methods to Optimize Mebendazole Treatment of Ovarian CancerP20GM135009 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Javier Antonio Jo · 2022 to 2026
$13.6M
Mentoring Translational Cancer Research in OklahomaP30GM154635 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muralidharan Jayaraman · 2024 to 2026
$4.3M
A novel framework for nanomedicine developmentR35GM150758 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Stefan Wilhelm · 2023 to 2026
$1.5M
NCI NIH HHS P30 CA225520NIGMS NIH HHS P20 GM135009NIGMS NIH HHS P30 GM154635NIGMS NIH HHS R35 GM150758
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are clinically established carriers for nucleic acid therapeutics and mRNA-based vaccines. Current LNP formulations often use poly(ethylene glycol) (PEG)-based surface modifications to enhance pharmacokinetics, colloidal stability, and shelf life. However, PEG moieties can elicit anti-PEG immune responses, reactogenicity, and hypersensitivity reactions. Here, we investigated heparosan (HEP), a naturally occurring, biodegradable polysaccharide, for mRNA-LNP surface engineering and mRNA delivery

Indexed as

Drug CarriersLipidsNanoparticlesPolysaccharidesRNA, MessengerAnimalsDisaccharidesFemaleHumansLiposomesMiceParticle SizePolyethylene GlycolsSurface PropertiesDisaccharidesDrug CarriersheparosanLipid NanoparticlesLipidsLiposomesPolyethylene GlycolsPolysaccharidesRNA, Messengerdrug deliveryheparosanlipid nanoparticlesmRNAnanomedicinePEG-free formulation

Identifiers

PMID42117531
PMCPMC13198436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.